Melanotan II comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-10. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
== Guinness World Records == The world's largest functioning ballpoint pen was made by Acharya Makunuri Srinivasa in India. The pen measures 5.5 metres (18 ft 0.53 in) long and weighs 37.23 kilograms (82.08 lb). The world's most popular pen is the Bic Cristal, with the 100 billionth model sold in September, 2006. The Bic Cristal was launched in December 1950 and roughly 57 are sold per second.
isoform.io is a database of AlphaFold2-generated structures of proposed splice isoforms in the human genome. It includes information from 237,275 human transcripts. It has been used to detect errors in the mRNA predictions for a handful of genes. AlphaFold has shown certain limitations. AlphaFold DB provides models of individual protein chains (monomers), rather than their biologically relevant complexes. Many protein regions are predicted with low confidence score, including the intrinsically disordered protein regions. Alphafold-2 was validated for predicting effects of point mutations on structure and free energy, with a partial success.
Cone snails, or cones, are highly venomous sea snails that constitute the family Conidae. Conidae is a taxonomic family (previously subfamily) of predatory marine gastropod molluscs in the superfamily Conoidea. As of 2014, cone snails are the only member of the superfamily Conoidea. Some previous classifications grouped the cone snails in a subfamily, Coninae. As of March 2015 Conidae contained over 800 recognized species, varying widely in size from lengths of 1.3 cm to 21.6 cm. Working in 18th-century Europe, Carl Linnaeus knew of only 30 species that are still considered valid. Fossils of cone snails have been found from the Eocene to the Holocene epochs. Cone snail species have shells that are roughly conical in shape. Many species have colorful patterning on the shell surface. Cone snails are almost exclusively tropical in distribution. All cone snails are venomous and capable of stinging. Cone snails use a modified radula tooth and a venom gland to attack and paralyze their prey before engulfing it. The tooth, which is likened to a dart or a harpoon, is barbed and can be extended some distance out from the head of the snail at the end of the proboscis. Cone snail venoms are mainly peptide-based, and contain many different toxins that vary in their effects. The sting of several larger species of cone snails can be serious, and even fatal to humans. Cone snail venom also shows promise for medical use.
Sources: en.wikipedia.org
Dorothy Mary Crowfoot Hodgkin (née Crowfoot; 12 May 1910 – 29 July 1994) was an English chemist who advanced the technique of X-ray crystallography to determine the structure of biomolecules, which became essential for structural biology. She received the 1964 Nobel Prize in Chemistry, and is the only British woman scientist to have been awarded a Nobel Prize. Among her most influential discoveries are the confirmation of the structure of penicillin as previously surmised by Edward Abraham and Ernst Boris Chain; and mapping the structure of vitamin B12, for which in 1964 she became the third woman to win the Nobel Prize in Chemistry. Hodgkin also elucidated the structure of insulin in 1969 after 35 years of work. Hodgkin used the name "Dorothy Crowfoot" until twelve years after marrying Thomas Lionel Hodgkin, when she began using "Dorothy Crowfoot Hodgkin". Hodgkin is referred to as "Dorothy Hodgkin" by the Royal Society (when referring to its sponsorship of the Dorothy Hodgkin fellowship), and by Somerville College. The National Archives of the United Kingdom refer to her as "Dorothy Mary Crowfoot Hodgkin". The case of her Nobel prize is inscribed 'Crowfoot Hodgkin'.
On 17 September, the "All American" Division conducted its fourth and final combat jump of World War II. Fighting off German counterattacks, the division captured its objectives between Grave, and Nijmegen. The division failed to initially capture Nijmegen Bridge when the opportunity presented itself early in the battle. When the British XXX Corps arrived in Nijmegen, six hours ahead of schedule, they found themselves having to fight to take a bridge that should have already been in Allied hands. In the afternoon of Wednesday 20 September 1944, the 82nd Airborne Division successfully conducted an opposed assault crossing of the Waal river. War correspondent Bill Downs, who witnessed the assault, described it as "a single, isolated battle that ranks in magnificence and courage with Guam, Tarawa, Omaha Beach. A story that should be told to the blowing of bugles and the beating of drums for the men whose bravery made the capture of this crossing over the Waal possible." The Market Garden salient was held in a defensive operation for several weeks until the 82nd was relieved by Canadian troops, and sent into reserve in France. During the operation, 19-year-old Private John R. Towle of the 504th PIR was posthumously awarded the 82nd Airborne Division's second Medal of Honor of World War II.
Iron-deficiency anemia is anemia caused by a lack of iron. Anemia is defined as a decrease in the number of red blood cells or the amount of hemoglobin in the blood. When onset is slow, symptoms are often vague, such as feeling tired, weak, short of breath, or having decreased ability to exercise. Anemia that comes on quickly often has more severe symptoms, including confusion, feeling like one is going to pass out or increased thirst. Anemia is typically significant before a person becomes noticeably pale. Children with iron deficiency anemia may have problems with growth and development. There may be additional symptoms depending on the underlying cause. Iron-deficiency anemia is caused by blood loss, insufficient dietary intake, or poor absorption of iron from food. Sources of blood loss can include heavy periods, childbirth, uterine fibroids, stomach ulcers, colon cancer, and urinary tract bleeding. Poor absorption of iron from food may occur as a result of an intestinal disorder such as inflammatory bowel disease or celiac disease, or surgery such as a gastric bypass. In the developing world, parasitic worms, malaria, and HIV/AIDS increase the risk of iron deficiency anemia. Diagnosis is confirmed by blood tests. Iron deficiency anemia can be prevented by eating a diet containing sufficient amounts of iron or by iron supplementation. Foods high in iron include meat, nuts, and foods made with iron-fortified flour.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.